Compared to monotherapy, JNJ-42756493 (FGFR inhibitor) plus AZD8055 or siolimus (mTOR inhibitor) has a more significant anti-tumor effect in organoids with FGFR3 mutations and nonsense TSC mutations [93]. The gene discussed is FGFR3; the disease is neoplasm.